← Leaderboards
Simon Akerman
University Of Maryland Baltimore
$1,348,526
Attributed
$3,093,832
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,093,832 · 2
By mechanism
R01$3,093,832 · 2
Top collaborators
- Daniela Salvemini6 shared
- Marcela Romero-Reyes2 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Daniela Salvemini$13,229,020
- Andrea M Harriott$996,028
- Michael S Gold$16,352,215
- Marcela Romero-Reyes$628,530
- Joyce Teixeira Da Silva$2,580,045
Others in their field
Other Rising Stars on “Migraine”
- Hadas Nahman-Averbuch · Washington University$3,001,664
- John Paderi John Paderi John Paderi · Ihp Therapeutics, Inc.$2,611,866
- Jane N Bolin · University Of Texas Hlth Sci Ctr Houston$2,266,499
- Cameron Reid Smith · University Of Florida$1,762,231
- Katharina Maria Busl · University Of Florida$1,762,231
- Gisela Chelimsky · Virginia Commonwealth University$1,550,726
Research focus
MigraineMediatingFemaleInterdisciplinary ApproachLinkMarenostrinDoseFamilyInsightInflammatoryInterleukin-1InvestigationBehavioralMaleBiochemicalClinical TranslationAntagonistElectrophysiology (Science)Genetic ApproachChronicAttenuatedInflammationAgonistMolecular
Grant awards (6)
Molecular basis for functional S1PR1 antagonists in the treatment of comorbid migraine and temporomandibular disorders$570,062
R01 · FY2025 · NS · contact PI
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine$472,920
R01 · FY2025 · NS · contact PI
Molecular basis for functional S1PR1 antagonists in the treatment of comorbid migraine and temporomandibular disorders$620,278
R01 · FY2024 · NS · contact PI
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine$458,732
R01 · FY2024 · NS · contact PI
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine$472,920
R01 · FY2023 · NS · contact PI
Molecular basis for adenosine A3 receptor agonists in the treatment of migraine$498,920
R01 · FY2022 · NS · contact PI